What we know as work has experienced a major transformation. This shift and the changes it precipitated have affected how we now conduct and perform monitoring of clinical trials.
Working in the pharmacovigilance area and protecting the safety of patients is challenging. With Veristat, you’ll bring more confidence to your post-marketing pharmacovigilance and safety surveillance for greater peace of mind.
April 2022
Each month, Veristat's regulatory team tracks and shares a selection of new Regulatory Guidance updates from the US Food & Drug Administration (FDA) that are pertinent to the governance of clinical trials and drug, biologic, or medical device development and approval. Below are the relevant links to updates provided for both COVID-19 related and non-COVID-19 related programs in April 2022.